Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry

References

• DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93–10. J Clin Oncol. 2002;20:4643–4648.
   PubMed Web of Science ®Google Scholar
• Pels H, Schmidt-Wolf IG, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21:4489–4495.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374:1512–1520.
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Marks R, Müller F, et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol. 2009;20:319–325.
   PubMed Web of Science ®Google Scholar
• Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11:1036–1047.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Licata G, Foppoli M, et al. Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. Oncologist. 2011;16:336–341.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Ciceri F, Brandes AA, et al. MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years. Neurology. 2014;82:1370–1373.
   PubMed Web of Science ®Google Scholar
• Birnbaum T, Bochmann K, von Baumgarten L, et al. Early relapses in patients with primary CNS lymphoma treated with methotrexate-based chemotherapy without consolidating whole brain irradiation. J Neurooncol. 2013;112:233–239.
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Müller F, Feuerhake F, et al. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008;93:147–148.
   PubMed Web of Science ®Google Scholar
• Kasenda B, Schorb E, Fritsch K, et al. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma-a long-term follow-up study. Ann Oncol. 2012;23:2670–2675.
   PubMed Web of Science ®Google Scholar
• Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125:1403–1410.
   PubMed Web of Science ®Google Scholar
• Chen YB, Batchelor T, Li S, et al. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer. 2015;121:226–233.
   PubMed Web of Science ®Google Scholar
• Korfel A, Elter T, Thiel E, et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica. 2013;98:364–370.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–116.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: Targeting the leptomeningeal compartment. Blood. 2003;101:466–468.
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Grossman SA, Mikkelsen T, et al. Rituximab mono-therapy for patients with recurrent primary CNS lymphoma. Neurology. 2011;76:929–930.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intra-ocular lymphoma. J Clin Oncol. 2007;25:1350–1356.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Li J, Chen L, et al . Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013;121:745–751.
   PubMed Web of Science ®Google Scholar
• Shah GD, Yahalom J, Correa DD, et al . Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma . J Clin Oncol. 2007;25:4730–4735.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Batchelor TT, Ferreri AJ, et al. International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034–5043.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: The international extranodal lymphoma study group experience. J Clin Oncol. 2003;21:266–272.
   PubMed Web of Science ®Google Scholar
• Mappa S, Marturano E, Licata G, et al. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Hematol Oncol. 2011;31:143–150.
   Web of Science ®Google Scholar
• Rubenstein JL, His ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31:3061–3068.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Johnston SK. High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro Oncol. 2010;12:736–744.
   PubMed Web of Science ®Google Scholar
• Fritsch K, Kasenda B, Hader C, et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol. 2011;22:2080–2085.
   PubMed Web of Science ®Google Scholar
• Holdhoff M, Ambady P, Abdelaziz A, et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014;83:235–239.
   PubMed Web of Science ®Google Scholar
• Madle M, Krämer I, Lehners N, et al. The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma. Ann Hematol. 2015;94:1853–1857.
   PubMed Web of Science ®Google Scholar
• Kansara R, Shenkier TN, Connors JM, et al. Rituximab with high-dose methotrexate in primary central nervous system lymphoma. Am J Hematol. 2015;90:1149–1154.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Blay JY, Reni M, et al. Addition of thiotepa and rituximab to antimetabolites significantly improves outcome in primary CNS lymphoma: first randomization of the IELSG32 trial. Hematol Oncol. 2015;33:103–104.
   Google Scholar